investors
Syncromune™ is well-positioned to develop a scalable platform for long-term, sustained growth. Our innovative technology provides the potential to treat numerous types of metastatic solid tumor cancers.
CORPORATE OVERVIEW
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way.
The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor neoantigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to educate T cells to induce a systemic anti-tumor response at the site of the treated tumor as well as metastases throughout the body.
PRESS RELEASES
UPCOMING EVENTS
DEC 6
DEC 13
PAST EVENTS
NOV 2
November 2nd – 4th, 2022
Miami, FL
Hyatt Regency Miami
NOV 8
37th Annual Meeting
November 8th – 12th, 2022
Boston, MA
COMPANY PRESENTATIONS
Contact Information
Danielle Hobbs
EVP, Investor Relations & Corporate Communications
Social Media
Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd. https://t.co/617YOehYqk
Read More
Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference
Read MoreRT @CancerResearch: June kicks off Cancer Immunotherapy Month™. Let's fuel the next scientific discoveries and breakthrough treatments thro…
Read MoreInsight about tumor microenvironment could boost cancer immunotherapy via @medical_xpress
Read MoreMathematical method developed to predict cancer and drug-specific immunotherapy efficacy via @medical_xpress
Read MoreSITC Cancer Immunotherapy Winter School | Training Program
Read MoreNew clues to prostate cancer: Why aggressive subtype can resist treatment via @medical_xpress
Read MoreKey type of immune cell 'self-renews' in humans, new study finds via @medical_xpress
Read MoreMap shows how cancer cells spread through the body via @medical_xpress
Read MoreDisclaimer
The information contained in our press releases and presentations should be considered accurate only as of the date it was originally issued. Syncromune™ disavows any obligation to update the information contained in these press releases and presentations after the date of their issuance.